Research programme: haematological malignancies therapeutics - HTG Therapeutics
Latest Information Update: 27 Apr 2023
At a glance
- Originator HTG Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Haematological malignancies
Highest Development Phases
- Research Haematological malignancies
Most Recent Events
- 25 Apr 2023 Research programme: haematological malignancies therapeutics - HTG Therapeutics is available for partnering as of 25 Apr 2023. https://www.htgmolecular.com/
- 09 Jan 2023 Early research in Haematological malignancies in USA (unspecified route) before January 2023